RAIN
-
News
wAIHA | Sovleplenib Demonstrates Positive Phase III Clinical Results
wAIHA is a rare autoimmune disorder in which the immune system produces antibodies that mistakenly target and destroy red blood cells, leading to anemia and significant clinical burden. The…
Read More » -
News
SICKLE CELL DISEASE | Alzheimer’s Drug Demonstrates Potential Therapeutic Benefit
The study explores the potential of memantine, a medication that has been safely used for many years in the treatment of Alzheimer’s disease. Researchers investigated whether this well-known, affordable drug…
Read More » -
News
SICKLE CELL DISEASE | Inflammation during Menstrual Cycle May Trigger Pain Crises
SCD is a genetic disorder in which red blood cells can become abnormally shaped (“sickle”), leading to blockages in blood vessels, tissue damage, and intense pain known as vaso-occlusive events…
Read More » -
News
SEVERE APLASTIC ANAEMIA | Stem Cell Transplant Opens New Possibilities
Severe aplastic anaemia is a rare but serious disorder in which the bone marrow fails to produce enough red and white blood cells or platelets. This results in fatigue, infections,…
Read More » -
News
SICKLE CELL DISEASE | Limited Progress in Sickle Cell Disease Highlights Barriers to Treatment Access
According to the findings, there has been limited improvement in outcomes for SCD patients, in large part due to barriers in accessing first-line therapies such as hydroxyurea. Although several new…
Read More » -
News
SICKLE CELL DISEASE | Intranasal Fentanyl Shows Promise for Rapid Pain Relief in Adults
Fentanyl is a powerful painkiller that has already been widely used in children with SCD and in adults with cancer or chronic pain. Researchers now believe its use in adults…
Read More » -
News
NEW STUDY | Pegcetacoplan Shows Potential in Managing CAD and wAIHA
This investigational therapy, which targets complement component C3, has demonstrated the ability to increase haemoglobin levels, reduce haemolysis, and improve fatigue scores, according to the study’s authors. Although not all…
Read More » -
News
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Patients May See Improved Outcomes with Ravulizumab
The findings showed that patients treated with ravulizumab demonstrated better adherence and persistence compared to those on other complement inhibitors. The ADVANTAGE study, a retrospective longitudinal analysis, included data from…
Read More » -
News
SICKLE CELL DISEASE | FDA Grants Orphan Drug Designation to AND017
Announced by KIND Pharmaceuticals on October 25, 2024, ODD is granted to a drug or biological product to prevent, diagnose, or treat a rare disease or condition that affects fewer…
Read More » -
News
Splenectomy as Treatment for Primary Warm Autoimmune Hemolytic Anemia (wAIHA)
Warm Autoimmune Hemolytic Anemia (wAIHA) occurs when the body’s immune system mistakenly produces antibodies that attack and destroy its own red blood cells. In this particular case, the patient presented…
Read More »